Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

Anderson, 2006, Predictors of mortality in patients with bloodstream infection due to ceftazidime‐resistant Klebsiella pneumoniae, Antimicrob Agents Chemother, 50, 1715, 10.1128/AAC.50.5.1715-1720.2006 Cosgrove, 2003, Comparison of mortality associated with methicillin‐resistant and methicillin‐susceptible Staphylococcus aureus bacteremia: a meta‐analysis, Clin Infect Dis, 36, 53, 10.1086/345476 Roberts, 2009, Hospital and societal costs of antimicrobial‐resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship, Clin Infect Dis, 49, 1175, 10.1086/605630 Ibrahim, 2000, The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting, Chest, 118, 146, 10.1378/chest.118.1.146 McGowan, 2006, Resistance in nonfermenting gram‐negative bacteria: multidrug resistance to the maximum, Am J Med, 119, 29, 10.1016/j.amjmed.2006.03.014 Bonomo, 2006, Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa, Clin Infect Dis, 43, 49, 10.1086/504477 Pitout, 2008, Extended‐spectrum [beta]‐lactamase‐producing Enterobacteriaceae: an emerging public‐health concern, Lancet Infect Dis, 8, 159, 10.1016/S1473-3099(08)70041-0 European Centre for Disease Prevention and Control/European Medicines Agency. ECDC/EMEA joint technical report: the bacterial challenge: time to react.: European centre for disease prevention and control & European medicines agency, Stockholm, Sweden & London, United Kingdom, 2009. Boucher, 2009, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin Infect Dis, 48, 1, 10.1086/595011 Falagas, 2006, The diversity of definitions of multidrug‐resistant (MDR) and pandrug‐resistant (PDR)Acinetobacter baumannii and Pseudomonas aeruginosa, J Med Microbiol, 55, 1619, 10.1099/jmm.0.46747-0 Goossens, 2003, Susceptibility of multi‐drug‐resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group, Clin Microbiol Infect, 9, 980, 10.1046/j.1469-0691.2003.00690.x Falagas, 2008, Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram‐negative bacilli: need for international harmonization in terminology, Clin Infect Dis, 46, 1121, 10.1086/528867 Apisarnthanarak, 2008, A multifaceted intervention to reduce pandrug‐resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3‐year study, Clin Infect Dis, 47, 760, 10.1086/591134 Doi, 2009, Extensively drug‐resistant Acinetobacter baumannii, Emerg Infect Dis, 15, 980, 10.3201/eid1506.081006 Park, 2009, Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea, Emerg Infect Dis, 15, 1325, 10.3201/eid1508.080772 Cohen, 2008, Recommendations for metrics for multidrug‐resistant organisms in healthcare settings: SHEA/HICPAC Position paper, Infect Control Hosp Epidemiol, 29, 901, 10.1086/591741 Hidron, 2008, NHSN annual update: antimicrobial‐resistant pathogens associated with healthcare‐associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007, Infect Control Hosp Epidemiol, 29, 996, 10.1086/591861 Paterson David, 2007, A step closer to extreme drug resistance (XDR) in gram‐negative bacilli, Clin Infect Dis, 45, 1179, 10.1086/522287 Carmeli, 2010, Controlling the spread of carbapenemase‐producing Gram‐negatives: therapeutic approach and infection control, Clin Microbiol Infect, 16, 102, 10.1111/j.1469-0691.2009.03115.x The Alliance for Prudent use of Antibiotics, 2005, Executive summary: select findings, conclusions, and policy recommendations, Clin Infect Dis, 41, 224, 10.1086/430781 Jones, 2001, Determining the value of antimicrobial surveillance programs, Diagn Microbiol Infect Dis, 41, 171, 10.1016/S0732-8893(01)00318-2 Tapsall, 2009, Meeting the public health challenge of multidrug‐ and extensively drug‐resistant Neisseria gonorrhoeae, Expert Rev Anti Infect Ther, 7, 821, 10.1586/eri.09.63 Richter, 2009, Changing epidemiology of antimicrobial‐resistant Streptococcus pneumoniae in the United States, 2004‐2005, Clin Infect Dis, 48, e23, 10.1086/595857 Parry, 2008, Antimicrobial resistance in typhoidal and nontyphoidal salmonellae, Curr Opin Infect Dis, 21, 531, 10.1097/QCO.0b013e32830f453a Hendriksen, 2009, WHO Global Salm‐Surv external quality assurance system for serotyping of Salmonella isolates from 2000 to 2007, J Clin Microbiol, 47, 2729, 10.1128/JCM.02437-08 Clinical and Laboratory Standards Institute, 2009 European Committee on Antimicrobial Susceptibility Testing (EUCAST) MacGowan, 2008, Clinical implications of antimicrobial resistance for therapy, J Antimicrob Chemother, 62, 105 Paterson, 2006, The epidemiological profile of infections with multidrug‐resistant Pseudomonas aeruginosa and Acinetobacter species, Clin Infect Dis, 43, 43, 10.1086/504476 Kallen, 2010, Multidrug resistance among gram‐negative pathogens that caused healthcare‐associated infections reported to the National Healthcare Safety Network, 2006‐2008, Infect Control Hosp Epidemiol, 31, 528, 10.1086/652152 Pillar, 2008, Prevalence of multidrug‐resistant, methicillin‐resistant Staphylococcus aureus in the United States: findings of the stratified analysis of the 2004 to 2005 LEADER Surveillance Programs, Diagn Microbiol Infect Dis, 60, 221, 10.1016/j.diagmicrobio.2007.08.007 Seas, 2006, Oxacillin‐resistant and multidrug‐resistant Staphylococcus aureus in Lima, Peru, Infect Control Hosp Epidemiol, 27, 198, 10.1086/500650 Jeong, 2007, Molecular epidemiology of community‐associated antimicrobial‐resistant Staphylococcus aureus in Seoul, Korea (2003): pervasiveness of multidrug‐resistant SCCmec type II methicillin‐resistant S. aureus, Microb Drug Resist, 13, 178, 10.1089/mdr.2007.709 Critchley, 2003, Activity of daptomycin against susceptible and multidrug‐resistant Gram‐positive pathogens collected in the SECURE study (Europe) during 2000–2001, J Antimicrob Chemother, 51, 639, 10.1093/jac/dkg130 O’Fallon, 2009, Colonization with multidrug‐resistant gram‐negative bacteria: prolonged duration and frequent cocolonization, Clin Infect Dis, 48, 1375, 10.1086/598194 Andrade, 2003, Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001), J Antimicrob Chemother, 52, 140, 10.1093/jac/dkg270 Gould, 2008, The epidemiology of antibiotic resistance, Int J Antimicrob Agents, 32, 2, 10.1016/j.ijantimicag.2008.06.016 Siegel, 2007, Management of multidrug‐resistant organisms in health care settings, 2006, Am J Infect Control, 35, 165, 10.1016/j.ajic.2007.10.006 Brink, 2008, Emergence of extensive drug resistance (XDR) among Gram‐negative bacilli in South Africa looms nearer, S Afr Med J, 98, 586 Tseng, 2007, Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii, Diagn Microbiol Infect Dis, 59, 181, 10.1016/j.diagmicrobio.2007.04.024 CDC, 2006, Emergence of Mycobacterium tuberculosis with extensive resistsance to second‐line drugs – Worldwide, 2000–2004, MMWR Morb Mortal Wkly Rep, 55, 301 CDC, 2006, Notice to readers: revised definition of extensively drug‐resistant tuberculosis, MMWR Morb Mortal Wkly Rep, 55, 1176 Kuo, 2004, Dissemination of a clone of unusual phenotype of pandrug‐resistant Acinetobacter baumannii at a university hospital in Taiwan, J Clin Microbiol, 42, 1759, 10.1128/JCM.42.4.1759-1763.2004 Kuo, 2003, Clinical features of pandrug‐resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan, J Formos Med Assoc, 102, 601 Ortega, 2004, Endemic multidrug‐resistant Pseudomonas aeruginosa in critically ill patients, Infect Control Hosp Epidemiol, 25, 825, 10.1086/502303 Lang, 2000, Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa, Am J Respir Crit Care Med, 162, 2241, 10.1164/ajrccm.162.6.2005018 Davies, 2003, Multiresistant Pseudomonas aeruginosa in a pediatric cystic fibrosis center: natural history and implications for segregation, Pediatr Pulmonol, 35, 253, 10.1002/ppul.10262 Dubois, 2001, Nosocomial outbreak Due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime‐amikacin therapy and analysis of {beta}‐lactam resistance, J Clin Microbiol, 39, 2072, 10.1128/JCM.39.6.2072-2078.2001 Pagani, 2005, Nosocomial outbreak caused by multidrug‐resistant Pseudomonas aeruginosa producing IMP‐13 metallo‐{beta}‐Lactamase, J Clin Microbiol, 43, 3824, 10.1128/JCM.43.8.3824-3828.2005 Jung, 2004, Surveillance of multi‐drug resistant Pseudomonas aeruginosa in an urban tertiary‐care teaching hospital, J Hosp Infect, 57, 105, 10.1016/j.jhin.2004.03.001 European Committee on Antimicrobial Susceptibility Testing (EUCAST) Komp Lindgren, 2003, Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections, Antimicrob Agents Chemother, 47, 3222, 10.1128/AAC.47.10.3222-3232.2003 Leclercq, 2002, Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications, Clin Infect Dis, 34, 482, 10.1086/324626